Lentigen Licenses Lentiviral IP from Cambridge

Apr 03, 2008

NEW YORK (GenomeWeb News) – Lentigen has licensed an HIV-related lentiviral vector technology patent held by the University of Cambridge, the company said today.

Baltimore-based Lentigen signed an exclusive agreement with Cambridge Enterprise, the technology licensing arm of the University of Cambridge, for technology that was developed by Andrew Lever.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Sharing, But Kinda Sorta

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

This Week in Science

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

Structural Biologist Leads India's CSIR

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

Upward of One Hundred

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Main menu